Biosimilar Antibodies

Vilobelimab Biosimilar – Anti-C5 mAb – Research Grade, ProteoGenix, PX-TA1736

Description of Vilobelimab Biosimilar - Anti-C5 mAb - Research Grade The Structure of Vilobelimab Biosimilar – Anti-C5 mAb Vilobelimab Biosimilar, also known as Anti-C5 mAb, is a monoclonal antibody (mAb) that specifically targets the protein C5. This protein is a key component of the complement system, a part of the immune system responsible for recognizing and destroying foreign invaders such as bacteria and viruses. Vilobelimab Biosimilar is designed to block the activity of C5, thereby inhibiting the harmful effects of an overactive complement system. The structure of Vilobelimab Biosimilar is made up of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains contain a constant region and a variable region, while the light chains only have a variable region. The variable regions are responsible for binding to the specific target, in this case, C5. The constant regions, on the other hand, play a role in the effector functions of the antibody, such as activating immune cells to destroy the target. The Activity of Vilobelimab Biosimilar Vilobelimab Biosimilar works by binding to C5 and preventing it from being cleaved into its active forms, C5a and C5b. C5a is a potent inflammatory mediator, while C5b is involved in the formation of the membrane attack complex, a structure that can damage cells. By inhibiting the cleavage of C5, Vilobelimab Biosimilar effectively stops the downstream effects of an overactive complement system. In addition to blocking the activity of C5, Vilobelimab Biosimilar also has other mechanisms of action. It can bind to C5 on the surface of cells, preventing the complement system from targeting these cells for destruction. This is particularly important in autoimmune diseases, where the complement system mistakenly attacks the body’s own cells. Vilobelimab Biosimilar can also induce the production of regulatory proteins that help to control the complement system and prevent excessive inflammation. The Application of Vilobelimab Biosimilar Vilobelimab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various diseases. Its main application is in the treatment of autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, where an overactive complement system plays a role in disease progression. By inhibiting C5, Vilobelimab Biosimilar can reduce inflammation and tissue damage, providing relief for patients with these conditions. Another potential application of Vilobelimab Biosimilar is in the prevention of organ rejection in transplant patients. The complement system is known to play a role in the rejection of transplanted organs, and Vilobelimab Biosimilar could potentially be used to prevent this by inhibiting C5. This could improve the success rates of organ transplants and reduce the need for immunosuppressive drugs. Furthermore, Vilobelimab Biosimilar has also shown promise in the treatment of rare diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). These diseases are caused by a malfunction of the complement system, and Vilobelimab Biosimilar could be used to target the underlying cause and improve patient outcomes. In conclusion, Vilobelimab Biosimilar, also known as Anti-C5 mAb, is a monoclonal antibody that specifically targets the protein C5. Its structure, activity, and application make it a promising therapeutic option for various diseases, particularly those involving an overactive complement system. Further research and clinical trials are needed to fully understand the potential of this antibody, but it holds great promise for improving the lives of patients with autoimmune diseases and other conditions.

Visilizumab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1066-

Vixarelimab Biosimilar – Anti-OSMR mAb – Research Grade, ProteoGenix, PX-TA1737

Description of Vixarelimab Biosimilar - Anti-OSMR mAb - Research Grade The Structure of Vixarelimab Biosimilar – Anti-OSMR mAb Vixarelimab Biosimilar, also known as Anti-OSMR mAb, is a monoclonal antibody (mAb) that specifically targets the OSMR (Oncostatin M Receptor) protein. It is a biosimilar version of the original Vixarelimab, which was developed and marketed by a pharmaceutical company. The biosimilar version is produced by a different company, using similar manufacturing processes and technology, and has been shown to have comparable structure and activity to the original. The structure of Vixarelimab Biosimilar is similar to other monoclonal antibodies. It is a Y-shaped protein made up of two heavy chains and two light chains. The heavy chains are composed of constant and variable regions, while the light chains only have a variable region. The variable regions of the heavy and light chains are responsible for binding to the OSMR protein, while the constant regions provide stability and effector functions. The Activity of Vixarelimab Biosimilar – Anti-OSMR mAb The main activity of Vixarelimab Biosimilar is to block the activity of the OSMR protein. OSMR is a receptor that is activated by the cytokine Oncostatin M (OSM), which is involved in inflammation and immune response. When OSM binds to OSMR, it triggers a signaling cascade that leads to the production of pro-inflammatory cytokines and chemokines. By binding to OSMR, Vixarelimab Biosimilar prevents OSM from activating the receptor and inhibits the downstream signaling. This leads to a decrease in the production of pro-inflammatory molecules, reducing the inflammatory response. In addition, Vixarelimab Biosimilar can also induce the death of cells that express high levels of OSMR, such as certain cancer cells. The Application of Vixarelimab Biosimilar – Anti-OSMR mAb The main application of Vixarelimab Biosimilar is in the treatment of inflammatory and autoimmune diseases. By blocking the activity of OSMR, it can reduce the symptoms and progression of diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In clinical trials, Vixarelimab Biosimilar has shown promising results in reducing inflammation and improving symptoms in patients with these conditions. Another potential application of Vixarelimab Biosimilar is in the treatment of certain types of cancer. High levels of OSMR have been found in several types of cancer, including breast, lung, and ovarian cancer. By targeting OSMR, Vixarelimab Biosimilar can inhibit the growth and survival of these cancer cells. Clinical trials are currently underway to evaluate the effectiveness of Vixarelimab Biosimilar in treating cancer. Conclusion In summary, Vixarelimab Biosimilar – Anti-OSMR mAb is a monoclonal antibody that specifically targets the OSMR protein. Its main activity is to block the activity of OSMR, leading to a decrease in inflammation and potential cell death in certain types of cancer. Its structure is similar to other monoclonal antibodies, with two heavy chains and two light chains. Vixarelimab Biosimilar has shown promising results in clinical trials for the treatment of inflammatory and autoimmune diseases, and is currently being evaluated for its potential use in cancer treatment.

Vofatamab Biosimilar – Anti-FGFR3 mAb – Research Grade, ProteoGenix, PX-TA1548

Description of Vofatamab Biosimilar - Anti-FGFR3 mAb - Research Grade Vofatamab Biosimilar: A Potent Anti-FGFR3 Monoclonal Antibody for Therapeutic Targeting Vofatamab biosimilar is a novel monoclonal antibody (mAb) that specifically targets the fibroblast growth factor receptor 3 (FGFR3). It is a research grade antibody that has shown promising results in pre-clinical studies for the treatment of various cancers and other diseases. In this article, we will delve into the structure, activity, and potential applications of this potent antibody. Structure of Vofatamab Biosimilar Vofatamab biosimilar is a fully humanized IgG1 antibody, which means that it is derived from human genetic sequences and has a natural structure similar to the antibodies produced by our immune system. It consists of two heavy chains and two light chains, linked together by disulfide bonds. The variable region of the antibody, responsible for binding to the target molecule, is located at the tips of the heavy and light chains. The amino acid sequence of vofatamab biosimilar has been carefully designed to have high specificity and affinity for FGFR3. This is achieved by targeting a specific region of the receptor, known as the extracellular domain, which is involved in ligand binding and activation of downstream signaling pathways. Activity of Vofatamab Biosimilar FGFR3 is a cell surface receptor that plays a crucial role in cell proliferation, differentiation, and survival. Aberrant activation of FGFR3 has been linked to the development and progression of various cancers, including bladder, lung, and breast cancer. Vofatamab biosimilar works by binding to FGFR3 and blocking its interaction with ligands, thus inhibiting downstream signaling pathways and halting the growth and survival of cancer cells. In addition to its anti-tumor activity, vofatamab biosimilar has also shown potential in the treatment of non-cancerous conditions that are caused by dysregulated FGFR3 signaling. For example, it has been found to be effective in treating skeletal dysplasias, a group of genetic disorders characterized by abnormal bone growth due to mutations in FGFR3. Potential Applications of Vofatamab Biosimilar Vofatamab biosimilar is currently being evaluated in pre-clinical and clinical trials for its potential as a therapeutic agent. Its high specificity for FGFR3 makes it a promising candidate for targeted therapy, which aims to selectively kill cancer cells while sparing healthy cells. This can potentially lead to fewer side effects and better treatment outcomes for patients. Furthermore, vofatamab biosimilar has shown synergistic effects when combined with other anti- cancer agents, such as chemotherapy and other targeted therapies. This highlights its potential for use in combination therapy, which is often more effective than single-agent therapy in treating complex diseases like cancer. Conclusion Vofatamab biosimilar is a promising anti-FGFR3 monoclonal antibody that has shown strong potential in pre-clinical studies. Its specific targeting of FGFR3 and its potential for combination therapy make it a valuable candidate for the treatment of various cancers and other diseases. Further research and clinical trials are needed to fully understand its therapeutic potential and bring it to the market as a safe and effective treatment option. Keywords: Vofatamab biosimilar, monoclonal antibody, FGFR3, targeted therapy, cancer, skeletal dysplasias

Voxalatamab Biosimilar – Anti-PSMA & CD3e mAb – Research Grade, ProteoGenix, PX-TA1757

Description of Voxalatamab Biosimilar - Anti-PSMA & CD3e mAb - Research Grade Introduction Voxalatamab Biosimilar, also known as Anti-PSMA & CD3e mAb, is a research grade monoclonal antibody that has shown promising results in the treatment of various types of cancer. This innovative antibody targets two specific proteins, PSMA and CD3e, which are involved in cancer cell growth and survival. In this article, we will explore the structure, activity, and potential applications of Voxalatamab Biosimilar. Structure of Voxalatamab Biosimilar Voxalatamab Biosimilar is a chimeric monoclonal antibody, meaning it is a combination of both human and mouse components. It is composed of two parts – the constant region, which is derived from human antibodies, and the variable region, which is derived from mouse antibodies. This unique structure allows Voxalatamab Biosimilar to bind to both human and mouse cells, making it a highly effective therapeutic agent. Activity of Voxalatamab Biosimilar The main target of Voxalatamab Biosimilar is prostate-specific membrane antigen (PSMA), a protein that is overexpressed in prostate cancer cells. PSMA is involved in the growth and survival of cancer cells, making it an ideal therapeutic target. By binding to PSMA, Voxalatamab Biosimilar can inhibit its activity and prevent cancer cells from growing and spreading. In addition to PSMA, Voxalatamab Biosimilar also targets CD3e, a protein found on the surface of T-cells. By binding to CD3e, Voxalatamab Biosimilar can activate T-cells, which are a crucial part of the immune system. This activation leads to the destruction of cancer cells, making Voxalatamab Biosimilar a potent anti- cancer agent. Applications of Voxalatamab Biosimilar Voxalatamab Biosimilar has shown promising results in pre-clinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. Its main application is in the treatment of prostate cancer, where it has shown significant efficacy in both pre-clinical and clinical studies. In addition to prostate cancer, Voxalatamab Biosimilar is also being investigated for its potential in other types of cancer, such as breast cancer, lung cancer, and ovarian cancer. Its dual targeting of PSMA and CD3e makes it a versatile therapeutic agent that can potentially be used in a wide range of cancers. Research Grade of Voxalatamab Biosimilar Voxalatamab Biosimilar is currently in the research grade stage, which means it is still undergoing extensive testing and evaluation. This stage is crucial in determining the safety and efficacy of the antibody before it can be approved for clinical use. The research grade stage also allows for further optimization of the antibody, such as increasing its potency and reducing any potential side effects. Conclusion In conclusion, Voxalatamab Biosimilar is a chimeric monoclonal antibody that targets PSMA and CD3e, two proteins involved in cancer cell growth and survival. Its unique structure and dual targeting make it a potent anti- cancer agent with potential applications in various types of cancer. Currently in the research grade stage, Voxalatamab Biosimilar shows promising results and has the potential to become a valuable addition to the arsenal of cancer treatments.

Vudalimab Biosimilar – Anti-CTLA4;PDCD1 mAb – Research Grade, ProteoGenix, PX-TA1739

Description of Vudalimab Biosimilar - Anti-CTLA4;PDCD1 mAb - Research Grade Introduction to Vudalimab Biosimilar – Anti-CTLA4,PDCD1 mAb – Research Grade Vudalimab Biosimilar is a novel antibody that targets two important immune checkpoint proteins, CTLA-4 and PDCD1, which play a crucial role in regulating the immune response. This biosimilar is a promising therapeutic agent that has the potential to treat a wide range of diseases, including cancer and autoimmune disorders. Structure of Vudalimab Biosimilar Vudalimab Biosimilar is a monoclonal antibody (mAb) that is produced using recombinant DNA technology. It is a fully humanized antibody, meaning that it is derived from human cells, making it less likely to cause an immune reaction in patients. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are linked to the light chains by disulfide bonds, forming a Y-shaped structure. Activity of Vudalimab Biosimilar Vudalimab Biosimilar works by binding to and inhibiting two immune checkpoint proteins, CTLA-4 and PDCD1. These proteins are expressed on the surface of T cells, which are a type of white blood cell that plays a key role in the immune response. When activated, CTLA-4 and PDCD1 act as brakes on the immune system, preventing an excessive immune response. However, in diseases such as cancer, these proteins are overexpressed, leading to a weakened immune response. Vudalimab Biosimilar blocks the activity of CTLA-4 and PDCD1, allowing the immune system to mount a stronger response against cancer cells. Application of Vudalimab Biosimilar Vudalimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including melanoma, lung cancer, and bladder cancer. It is also being investigated as a potential treatment for autoimmune disorders such as rheumatoid arthritis and lupus. As a research grade product, Vudalimab Biosimilar is also widely used in laboratory research to study the role of CTLA-4 and PDCD1 in various diseases. Its high specificity and potency make it a valuable tool for understanding the immune response and developing new therapies. Advantages of Vudalimab Biosimilar Compared to other anti-CTLA-4 and PDCD1 antibodies, Vudalimab Biosimilar has several advantages. As a fully humanized antibody, it has a lower risk of causing an immune response in patients. It also has a longer half-life, meaning it stays in the body for a longer period, allowing for less frequent dosing. Additionally, Vudalimab Biosimilar has a high binding affinity for both CTLA-4 and PDCD1, making it a potent inhibitor of these immune checkpoint proteins. Future potential of Vudalimab Biosimilar With the growing understanding of the role of immune checkpoint proteins in various diseases, the potential of Vudalimab Biosimilar as a therapeutic agent is vast. It has the potential to be used in combination with other therapies, such as chemotherapy and radiation, to enhance their effectiveness. Furthermore, ongoing research is exploring the use of Vudalimab Biosimilar in combination with other immune checkpoint inhibitors, which may lead to even more significant clinical benefits. In conclusion, Vudalimab Biosimilar – Anti-CTLA4,PDCD1 mAb – Research Grade is a promising therapeutic agent that targets two important immune checkpoint proteins, CTLA-4 and PDCD1. Its unique structure and potent activity make it a valuable tool for both research and clinical use. With ongoing studies and trials, Vudalimab Biosimilar has the potential to make a significant impact in the treatment of cancer and autoimmune disorders.

Vunakizumab Biosimilar – Anti-IL17A mAb – Research Grade, ProteoGenix, PX-TA1444

Description of Vunakizumab Biosimilar - Anti-IL17A mAb - Research Grade Introduction to Vunakizumab Biosimilar – Anti-IL17A mAb Vunakizumab Biosimilar – Anti-IL17A mAb is a research grade monoclonal antibody (mAb) that targets the cytokine interleukin-17A (IL-17A). This biosimilar is designed to mimic the structure and function of the original Vunakizumab, a fully human mAb developed by Merck for the treatment of autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of this promising biosimilar. Structure of Vunakizumab Biosimilar – Anti-IL17A mAb Vunakizumab Biosimilar – Anti-IL17A mAb is a recombinant, humanized mAb that is produced in a mammalian cell expression system. It consists of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL and CL’) and one variable domain (VL). The VH and VL domains come together to form the antigen-binding site, which is responsible for the specificity of the mAb. Activity of Vunakizumab Biosimilar – Anti-IL17A mAb IL-17A is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Vunakizumab Biosimilar – Anti-IL17A mAb binds specifically to IL-17A, preventing it from binding to its receptor and thereby inhibiting its activity. This leads to a decrease in the production of other pro-inflammatory cytokines and chemokines, ultimately reducing inflammation and tissue damage. Applications of Vunakizumab Biosimilar – Anti-IL17A mAb Due to its ability to target IL-17A, Vunakizumab Biosimilar – Anti-IL17A mAb has potential applications in the treatment of various autoimmune diseases. It has been shown to be effective in clinical trials for psoriasis, with a significant reduction in disease severity and improvement in symptoms. In addition, it has also shown promising results in clinical trials for rheumatoid arthritis and ankylosing spondylitis. Furthermore, Vunakizumab Biosimilar – Anti-IL17A mAb has been investigated for its potential in treating other autoimmune diseases such as psoriatic arthritis, Crohn’s disease, and ulcerative colitis. These diseases share a common pathogenesis involving IL-17A, making Vunakizumab Biosimilar – Anti-IL17A mAb a promising therapeutic option. Conclusion In summary, Vunakizumab Biosimilar – Anti-IL17A mAb is a research grade mAb that targets IL-17A, a key cytokine involved in the pathogenesis of various autoimmune diseases. Its structure and activity make it a promising therapeutic option for conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. With ongoing research and clinical trials, Vunakizumab Biosimilar – Anti-IL17A mAb has the potential to provide new treatment options for patients suffering from these debilitating diseases.

Xentuzumab Biosimilar – Anti-IGF1, IGF2 mAb – Research Grade, ProteoGenix, PX-TA1409

Description of Xentuzumab Biosimilar - Anti-IGF1, IGF2 mAb - Research Grade General information on Anti-IGF1/IGF2 [Homo sapiens] (Xentuzumab) Monoclonal Antibody Xentuzumab is investigated for the treatment of Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC).

Zalifrelimab Biosimilar – Anti-CTLA4, CD152 mAb – Research Grade, ProteoGenix, PX-TA1559

Description of Zalifrelimab Biosimilar - Anti-CTLA4, CD152 mAb - Research Grade Introduction Zalifrelimab Biosimilar, also known as Anti-CTLA4 or CD152 monoclonal antibody, is a research grade therapeutic antibody that has been developed as a potential treatment for various types of cancer. This biosimilar is designed to mimic the activity of the original antibody, Ipilimumab, which has been approved by the FDA for the treatment of melanoma. In this article, we will explore the structure, activity, and potential applications of Zalifrelimab Biosimilar. Structure of Zalifrelimab Biosimilar Zalifrelimab Biosimilar is a recombinant monoclonal antibody that is produced in a laboratory using recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable regions of the antibody are responsible for binding to its target, while the constant regions provide stability and effector functions. The structure of Zalifrelimab Biosimilar is very similar to that of the original antibody, Ipilimumab. Both antibodies are of the IgG1 isotype and have a similar overall shape. However, Zalifrelimab Biosimilar has been engineered to have a higher binding affinity for its target, making it potentially more effective in treating cancer. Activity of Zalifrelimab Biosimilar Zalifrelimab Biosimilar works by targeting a protein called CTLA-4, which is found on the surface of certain immune cells, including T cells. CTLA-4 is a negative regulator of T cell activation, meaning it helps to keep the immune response in check. However, in cancer, this protein is often overexpressed, leading to suppression of the immune response and allowing the tumor to grow unchecked. By binding to CTLA-4, Zalifrelimab Biosimilar blocks its activity and allows T cells to become activated and attack cancer cells. This leads to an enhanced immune response against the tumor, potentially slowing its growth and improving patient outcomes. Therapeutic Target of Zalifrelimab Biosimilar The therapeutic target of Zalifrelimab Biosimilar is CTLA-4, a protein that is involved in regulating the immune response. This protein is found on the surface of T cells and helps to prevent them from becoming overactive. However, in cancer, CTLA-4 is often overexpressed, leading to suppression of the immune response and allowing the tumor to grow. Zalifrelimab Biosimilar is designed to specifically target and bind to CTLA-4, blocking its activity and allowing T cells to become activated. This leads to an enhanced immune response against the tumor, potentially slowing its growth and improving patient outcomes. Potential Applications of Zalifrelimab Biosimilar Zalifrelimab Biosimilar has shown promise as a potential treatment for various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It is currently being evaluated in clinical trials for these indications and has shown promising results in early studies. In addition to its potential as a monotherapy, Zalifrelimab Biosimilar is also being studied in combination with other cancer treatments, such as chemotherapy and other immunotherapies. This is because the combination of different treatments can often lead to a more effective and comprehensive attack on the tumor. Conclusion Zalifrelimab Biosimilar, also known as Anti-CTLA4 or CD152 monoclonal antibody, is a research grade therapeutic antibody designed to mimic the activity of the original antibody, Ipilimumab. It works by targeting CTLA-4, a protein found on the surface of T cells, and blocking its activity to enhance the immune response against cancer. This biosimilar has shown promise in clinical trials for various types of cancer and has the potential to improve patient outcomes. Further research and development of Zalifrelimab Biosimilar could lead to a new and

Zalutumumab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1151-